# Dyslipidemia and development of chronic kidney disease in non-diabetic Japanese adults: a 26-year, community-based, longitudinal study

## Author's affiliation

Yukari Okawa[1,2] and Toshiharu Mitsuhashi[3]

[1]Department of Public Health and Welfare, Zentsuji City Hall, 2-1-1 Bunkyo-cho, Zentsuji, Kagawa 765-8503, Japan
[2]Clinical Research Institute, Ohara HealthCare Foundation, 1-1-1 Miwa, Kurashiki, Okayama 710-8602, Japan
[3]Center for Innovative Clinical Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

## ORCiD

Yukari Okawa: https://orcid.org/0000-0002-1704-6609
Toshiharu Mitsuhashi: https://orcid.org/0000-0001-9940-0570

## Corresponding author

Yukari Okawa
Department of Public Health and Welfare, Zentsuji City Hall, 2-1-1 Bunkyo-cho, Zentsuji, Kagawa 765-8503, Japan
Tel.	+81 877 63 6308
Fax.	+81 877 63 6368
E-mail	okw3923@gmail.com

## Abstract

Follow-up studies evaluating the relationship between dyslipidemia and chronic kidney disease (CKD) in non-diabetic populations are limited. This longitudinal study (1998–2024) examined whether the prevalence of dyslipidemia is associated with the subsequent development of CKD in non-diabetic Japanese adult citizens of Zentsuji, Kagawa Prefecture, Japan. Dyslipidemia was defined as low-density lipoprotein cholesterol concentrations ≥140 mg/dL, high-density lipoprotein cholesterol concentrations <40 mg/dL, and/or triglyceride concentrations ≥150 mg/dL. Participants were considered to have developed CKD if their estimated glomerular filtration rate was <60 mL/min/1.73 m$^2$. The proportional hazard assumptions were violated. Therefore, the Weibull accelerated failure-time model was selected using the Akaike and Bayesian information criteria. The final cohort included 5970 participants, 41.6% of whom were men. The mean follow-up was 7.09 years. After the follow-up, 1890 (31.7%) participants developed CKD. Participants with dyslipidemia had a 5% shorter survival time (95% confidence interval: 3%–7%) to incident CKD compared with those without dyslipidemia in the full model. High-density lipoprotein cholesterol concentrations <40 mg/dL and triglyceride concentrations

≥150 mg/dL also reduced the survival time to CKD onset by 5%–6%. Our results provide further evidence that controlling the lipid profile to an appropriate range may prevent the future onset of CKD.

## Keywords

Cholesterol, HDL; Cholesterol, LDL; Chronic kidney disease; Dyslipidemias; Longitudinal studies; Public health; Risk factors; Survival analysis; Triglycerides.

## Introduction

Dyslipidemia is often comorbid with chronic kidney disease (CKD)[1]. However, the causal relationship between dyslipidemia and incident CKD remains controversial. Follow-up studies from the United Kingdom (UK) Biobank (n = 373,523) and China (n = 5183) reported that dyslipidemia was a risk factor for subsequently developing CKD[2,3]. In contrast, in a cohort study of the Japanese general population (n = 289,462), the exposure and outcome variables were reversed; prevalent CKD was a risk factor for high triglyceride (TG) concentrations and low high-density lipoprotein cholesterol (HDL-C) concentrations[4].

One explanation for this disagreement between studies may be different definitions of CKD used in each study. An estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m$^2$ and CKD diagnosis based on health records were used in the UK Biobank study, an eGFR <60 mL/min/1.73 m$^2$ was used in the Chinese study, and an eGFR <60 mL/min/1.7 3m$^2$ and/or prevalent proteinuria was used in the Japanese study[2–4]. To assess whether dyslipidemia or CKD occurs first, further evidence from longitudinal studies is required.

Another factor that may affect this consistency between studies is diabetes. Insulin deficiency and hyperglycemia due to diabetes cause changes in plasma lipoproteins, leading to dyslipidemia, and hyperglycemia due to diabetes constantly damages renal vessels, causing CKD[5,6]. Moreover, prevalent diabetes is associated with various diseases (e.g., diabetic nephropathy, cancer, and death), which cause bias when investigating the relationship between dyslipidemia and CKD. Therefore, removing the effect of diabetes by restricting participants to those without diabetes is effective in examining the relationship between dyslipidemia and incident CKD in more detail, rather than simply adjusting for diabetes as a covariate.

In recent years, the global prevalence of dyslipidemia and CKD has been high, with estimated percentages of 34.1% and 9.1%, respectively[7,8]. Additionally, prevalent CKD accounted for 1.2 million deaths worldwide in 2017[8]. Therefore, determining the relationship between dyslipidemia and CKD for the primary prevention of CKD and health promotion is important. This longitudinal analysis aimed to examine the relationship between dyslipidemia and new-onset CKD in a non-diabetic adult population.

## Materials and Methods

### Participants

This population-based, longitudinal study used data from an annual checkup (1998–2024) of Zentsuji City, Kagawa Prefecture, Japan[9]. All citizens aged ≥40 years can have checkups (participation ratio: 30%–40%). These checkups include measurement of height, weight, and blood pressure, urinalysis, a blood test, an elec-

trocardiogram, and a questionnaire about their lifestyle, such as alcohol intake and the smoking status. In Zentsuji City's pilot initiative to promote the health of younger citizens, this city included citizens aged 35–39 years in the eligible criteria for the 1998–1999 fiscal year only. The checkup followed the protocol by the Ministry of Health, Labour and Welfare of Japan[10]. We extracted the data on 1 July 2024, using the same database as that used in previous studies[11,12].

On the basis of our study aim, the following exclusion criteria were applied: a) non-Japanese citizenship, b) missing data of the prevalence of CKD, c) participants with CKD at study entry, d) missing data of the lipid profile, d) missing hemoglobin A1C (HbA1c) values, e) participants with HbA1c values ≥6.5% at study entry, and f) missing data with a small proportion of missing values (only 3 time points for BMI and 2 for liver enzymes), and g) participants with data at a single time point[13]. Participants who had HbA1c values ≥6.5% during the follow-up were treated as censored.

**Variables**

The exposure variable was dyslipidemia. The definitions of dyslipidemia vary according to the guidelines[14]. This study included only Japanese participants. Therefore, the following Japan Atherosclerosis Society guideline definition of dyslipidemia was selected: low-density lipoprotein cholesterol (LDL-C) concentrations ≥140 mg/dL, HDL-C concentrations <40 mg/dL, and/or TG concentrations ≥150 mg/dL[15].

The primary outcome measure was the onset of CKD. CKD was defined as an eGFR <60 mL/min/1.73 m$^2$[16]. The three-variable equation for Japanese was used to calculate the eGFR: eGFR (mL/min/1.73 m$^2$) = 194 × serum creatinine$^{-1.094}$ (mg/dL) × age$^{-0.287}$ (years) (× 0.739 if female)[13]. Serum creatinine concentrations were measured using enzymatic methods.

To minimize the effect of confounding factors, the following covariates were adjusted for: sex (male [reference]/female), age (continuous, in years), overweight or obesity (no [reference]/yes), self-reported smoking status (non- or ex-smoker [reference]/smoker), self-reported alcohol intake (non-drinker or seldom drinker [reference]/drinker), hypertension [no [reference]/yes], HbA1c (continuous, in %), liver function test results (aspartate aminotransferase [AST], alanine aminotransferase [ALT], and gamma-glutamyl transferase [gGTP]; continuous, in U/L), and residence area in Zentsuji City (east [reference]/south/Tatsukawa/Fudeoka/central/west/Yoshiwara/Yogita). Overweight or obesity was defined as a body mass index (BMI) ≥25 kg/m$^2$[17]. The participants were treated as hypertensive if their systolic blood pressure was ≥130 mmHg and/or diastolic blood pressure was ≥80 mmHg[18]. HbA1c values according to the Japan Diabetes Society (JDS) value was converted to HbA1c values according to the National Glycohemoglobin Standardization Program (NGSP) from 1998 to 2012: HbA1c$_{NGSP}$ (%) = 1.02 × HbA1c$_{JDS}$ (%) + 0.25 (%)[19].

**Statistical analysis**

Person-years were calculated from the first to the last observation date, or to the date of developing CKD or diabetes. The participants' characteristics were compared according to prevalent dyslipidemia. Categorical variables were compared by the total number of failures, total person-years, and incidence rate per 1000 person-years. Continuous variables are shown as the mean and standard deviation (SD). Kaplan–Meier curves are stratified by prevalent dyslipidemia.

The parametric model was selected in this analysis because the proportional hazard assumption was violated using the Schoenfeld residuals and the log–log plot[20]. The Weibull accelerated failure-time model

was selected under the Akaike and Bayesian information criteria[21,22]. To evaluate the effect of covariates, four adjusted models were applied. Model 1 was adjusted for sex and age. Model 2 was further adjusted for overweight or obesity, self-reported smoking status, and self-reported alcohol intake. Model 3 was further adjusted for hypertension, HbA1c, AST, ALT, and gGTP. Model 4 was further adjusted for the residential area of the city. To stabilize the models, a multiplicative term was added if the exposure variable had an interaction effect with sex, age, overweight or obesity, self-reported smoking status, self-reported alcohol intake, hypertension, HbA1c, AST, ALT, or gGTP.

Two sensitivity analyses were conducted in this study. First, LDL-C, HDL-C, and TGs were separately treated as exposure variables. LDL-C, HDL-C, and TG concentrations were classified into the following three categories: LDL-C concentrations <120 (reference), 120–<140, and ≥140 mg/dL; HDL-C concentrations <40, 40–<60, and ≥60 mg/dL (reference); and TG concentrations <100 (reference), 100–<150, and ≥150 mg/dL[15]. Second, participants with an eGFR <60 mL/min/1.73 $m^2$ and/or prevalent proteinuria ≥1+ were regarded as having prevalent CKD[23].

Missing values of the self-reported smoking status (24.6% of the total observations), self-reported alcohol intake (25.4% of the total observations), and the residential area (1.50% of the total observations) were imputed using multiple imputation methods (30 imputations)[24]. In this analysis, a two-tailed p value <0.05 was regarded as statistically significant. All statistical analysis was conducted using Stata/MP 16.1 (StataCorp, College Station, TX, USA). A flowchart of the participants was created by Python 3.11.5[25,26]. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline[27].

**Results**

This number of initial participants was 15,788 (41.0% men; 34–103 years old; 124,156 observations). After applying the exclusion criteria, our final cohort included 5970 participants (41.6% men; 39–103 years old; 40,942 observations), with a mean follow-up of 7.09 years (**Figure 1**). Kaplan–Meier curves by the dyslipidemia category are shown in **Figure 2**. The Kaplan–Meier curve showed that the survival rate was slightly lower in the dyslipidemia group than in the normal lipid profile group (log-rank p<0.001). **Table 1** shows the distribution of variables by prevalent dyslipidemia during the follow-up. Prevalent dyslipidemia had a higher incidence ratio than the normal lipid profile.

The relationship between dyslipidemia and subsequent onset of CKD is shown in **Table 2**. Regardless of whether the covariates were adjusted, prevalent dyslipidemia showed a shorter survival time to later onset CKD than lipids in the normal range, and this survival time was 5% shorter (95% confidence interval [CI]: 3%–7%) in the full model. When we separately evaluated the associations between LDL-C, HDL-C, and TG concentrations and the development of CKD in the first sensitivity analysis (**Table S1**), HDL-C concentrations <40 mg/dL and TG concentrations ≥150 mg/dL had a 5% shorter survival time (95% CI: 3%–7%) to CKD onset than the normal lipid profile (HDL-C concentrations ≥60 mg/dL and TG concentrations <100 mg/dL). In contrast, elevated LDL-C concentration categories (120–<140 mg/dL and ≥140 mg/dL) had an adjusted time ratio of 1.00 (0.99–1.02), which was almost the null value, compared with LDL concentrations <120 mg/dL.

**Table S2** shows the results of the second sensitivity analysis that examined how the results changed after using the definition of CKD of an eGFR <60 mL/min/1.73 $m^2$ and/or prevalent proteinuria ≥1+. The re-

sults were slightly attenuated compared with those of the main results shown in **Table 2**. Prevalent dyslipidemia shortened the survival time to CKD onset by 4% (95% CI: 2%–6%) in the full model.

Discussion

This 26-year longitudinal study showed that prevalent dyslipidemia reduced the survival time to CKD onset by 5%, even in a non-diabetic population. This study adds further evidence that dyslipidemia may be a risk factor for new-onset CKD late in life, even in a non-diabetic Asian population. The strengths of this study are that it included a mono-ethic Asian adult population without diabetes, had a long follow-up time of up to approximately 26 years (**Table 1**), and used the parametric accelerated failure-time model to attempt to reduce the effect of changes in covariates over time during the follow-up.

A previous UK Biobank cohort study showed an association between lipid concentrations (LDL-C, HDL-C, and TG) and the risk of CKD[3]. Similarly, a study in the general Chinese population showed an association between dyslipidemia and CKD development, with higher TG concentrations increasing the risk of CKD [2]. However, the results of LDL-C concentrations in these studies are different from those in our study. Our findings regarding the associations between HDL-C (<40 mg/dL) and TG (≥150 mg/dL) concentrations and a shorter survival time to CKD onset are in agreement with these two previous studies, but elevated LDL-C concentrations were not related to survival (**Table S1**).

There are four possible reasons for the inconsistent LDL-C results between studies. First, only a few studies examined the relationship between dyslipidemia and the later development of CKD, and all of these studies used different definitions of dyslipidemia[2,3]. This study used the cutoff values in accordance with the Japan Atherosclerosis Society guideline, the UK Biobank study standardized lipid profiles with a 1-SD increase, and the Chinese study used quartiles as cutoff values for the lipid profile[2,3,15]. This difference in the standard may be part of the reason why the LDL-C results are different between studies. Second, differences in the study participants may have affected the results. This study only included non-diabetic Japanese participants, and the UK Biobank study and Chinese general population study included participants with and without diabetes[2,3]. Furthermore, the current study and the Chinese study included East Asian populations, but the UK Biobank study only included the White participants. These differences between study populations may have affected the LDL results because diabetes is a leading cause of CKD, and the prevalence of diabetes is higher in Asians than in White populations[13,16,28]. Third, differences in the follow-up time between the studies may have affected the LDL results. The follow-up period (median follow-up) was 1998–2024 (6.04 years) in this study, 2006–2019 (10.7 years) in the UK Biobank study, and 2011–2016 (the median follow-up time was not shown) in the Chinese study. A longer follow-up time may induce built-in selection bias, which leads to an underestimation of the LDL results. Therefore, the results of this study and the UK Biobank study may have been underestimated[29]. Fourth, differences in selecting variables for adjustments may have affected the LDL results. Both of the previous studies further adjusted for variables, such as statin use, fibrate use, fasting time, blood urea nitrogen concentrations, and uric acid concentrations, which were not available in this study. The participants may have been using cholesterol-lowering medications (e.g., statins and fibrate) or had eaten before collecting blood. In this situation, more dyslipidemic participants would have been classified as normolipidemic, and more normolipidemic participants would have been classified as dyslipidemic, which would have led to non-differential misclassification. Because higher blood urea nitrogen or uric acid

concentrations increase the risk of reduced renal function, the unavailability of this information may have led to an overestimation of LDL results [30,31].

### Limitations

There are several limitations to this study. First, the characteristics of the participants in this study and the previous two studies mentioned above were different[2,3]. The participants in our study were healthier and older than those in the other two studies. Various outcomes related to prevalent diabetes, such as diabetic nephropathy, stroke, heart failure, activities of daily living disability falls, all-cause dementia, depression, cancer, hospitalization, and death, have been reported [32,33]. This study only included participants without diabetes and checkup participation was completely voluntary. Consequently, people with illnesses serious enough to prevent them from performing checkups and the effects of diabetes complications were absent. Therefore, all results of this study are considered to have been underestimated.

Second, the participants in this study had a mean age of 66.2 years (range: 39–103 years) (**Table 1**). Therefore, generalizing the results to other populations with different age structures may be limited. However, our findings may be more applicable to developed countries with aging Asian populations.

Third, the vulnerability of the eGFR may have affected our results. Therefore, we used the CKD criteria using an eGFR <60 mL/min/1.73 $m^2$ and proteinuria ≥1+ (**Table S2**)[23]. These results were consistent with the main analysis (**Table 2**), which indicated that these differences in the definition of CKD did not affect the results. Finally, we were unable to adjust for unmeasured important covariates, such as medications, the prevalence of diseases that affect both exposure and outcome variables, blood urea nitrogen and uric acid as noted above, hospitalization, and death. This is a limitation that cannot be ignored, but these covariates cannot be adjusted for. In particular, hospitalization and death are competing risks that preclude obtaining incident CKD data. Therefore, if competing risks were present in this study, the results could have been underestimated.

### Conclusions

This longitudinal study shows that dyslipidemia is an independent risk factor for the later development of CKD in a non-diabetic Japanese population, with a 5% shorter survival time to the development of CKD. Elevated TG concentrations ≥150 mg/dL and low HDL-C concentrations <40mg/dL, but not elevated LDL-C concentrations ≥140 mg/dL, also result in a 5%–6% shorter survival to CKD than the reference category. Our findings suggest that controlling the lipid profile to the normal range will be beneficial for future public health efforts to prevent CKD.

### Ethic

The data was anonymized before receipt. The Ethics Committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital approved this study (No. K1708-040). The Ethics committee waived the need for informed consent. This research followed the Declaration of Helsinki and Japanese Ethical Guidelines for Medical and Biological Research involving Human Subjects.

**Funding**

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflict of interest**

Yukari Okawa is an employee of Zentsuji City. Toshiharu Mitsuhashi has no conflict of interest to declare.

**Acknowledgments**

We thank all participants in this study, Ayaka Nakatsu, Masako Matsumoto, Mayumi Kitadani, and the local government officers of Zentsuji City who kindly supported our research. We thank Ellen Knapp, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

**Author Contributions**

Conceptualization, Y.O.; methodology, Y.O., T.M.; formal analysis, Y.O.; investigation, Y.O.; data curation, Y.O.; writing—original draft preparation, Y.O.; writing—review and editing, Y.O., T.M.; visualization, Y.O.; supervision, T.M.; project administration, Y.O. This manuscript has been read and approved by both authors.

**References**

1. Bermúdez-López, M.; Arroyo, D.; Betriu, À.; Masana, L.; Fernández, E.; Valdivielso, J.M. New Perspectives on CKD-Induced Dyslipidemia. *Expert Opinion on Therapeutic Targets* **2017**, *21*, 967–976, doi:10.1080/14728222.2017.1369961.
2. Liang, X.; Ye, M.; Tao, M.; Zheng, D.; Cai, R.; Zhu, Y.; Jin, J.; He, Q. The Association between Dyslipidemia and the Incidence of Chronic Kidney Disease in the General Zhejiang Population: A Retrospective Study. *BMC Nephrol* **2020**, *21*, 252, doi:10.1186/s12882-020-01907-5.
3. Weon, B.; Jang, Y.; Jo, J.; Jin, W.; Ha, S.; Ko, A.; Oh, Y.K.; Lim, C.S.; Lee, J.P.; Won, S.; et al. Association between Dyslipidemia and the Risk of Incident Chronic Kidney Disease Affected by Genetic Susceptibility: Polygenic Risk Score Analysis. *PLoS ONE* **2024**, *19*, e0299605, doi:10.1371/journal.pone.0299605.
4. Kosugi, T.; Eriguchi, M.; Yoshida, H.; Tasaki, H.; Fukata, F.; Nishimoto, M.; Matsui, M.; Samejima, K.; Iseki, K.; Fujimoto, S.; et al. Association between Chronic Kidney Disease and New-Onset Dyslipidemia: The Japan Specific Health Checkups (J-SHC) Study. *Atherosclerosis* **2021**, *332*, 24–32, doi:10.1016/j.atherosclerosis.2021.08.004.
5. Goldberg, I.J. Diabetic Dyslipidemia: Causes and Consequences. *The Journal of Clinical Endocrinology & Metabolism* **2001**, *86*, 965–971, doi:10.1210/jcem.86.3.7304.
6. Shen, Y.; Cai, R.; Sun, J.; Dong, X.; Huang, R.; Tian, S.; Wang, S. Diabetes Mellitus as a Risk Factor for Incident Chronic Kidney Disease and End-Stage Renal Disease in Women Compared with Men: A Systematic Review and Meta-Analysis. *Endocrine* **2017**, *55*, 66–76, doi:10.1007/s12020-016-1014-6.

7. López-Bueno, R.; Núñez-Cortés, R.; Calatayud, J.; Salazar-Méndez, J.; Petermann-Rocha, F.; López-Gil, J.F.; Del Pozo Cruz, B. Global Prevalence of Cardiovascular Risk Factors Based on the Life's Essential 8 Score: An Overview of Systematic Reviews and Meta-Analysis. *Cardiovascular Research* **2024**, *120*, 13–33, doi:10.1093/cvr/cvad176.

8. Bikbov, B.; Purcell, C.A.; Levey, A.S.; Smith, M.; Abdoli, A.; Abebe, M.; Adebayo, O.M.; Afarideh, M.; Agarwal, S.K.; Agudelo-Botero, M.; et al. Global, Regional, and National Burden of Chronic Kidney Disease, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. *The Lancet* **2020**, *395*, 709–733, doi:10.1016/S0140-6736(20)30045-3.

9. Zentsuji City Zentsuji City official website Available online: https://www.city.zentsuji.kagawa.jp (accessed on 23 October 2024).

10. Ministry of Health, Labour and Welfare Specific health examination and specific health guidance Available online: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000161103.html (accessed on 23 October 2024).

11. Okawa, Y.; Suzuki, E.; Mitsuhashi, T.; Tsuda, T.; Yorifuji, T. A Population-Based Longitudinal Study on Glycated Hemoglobin Levels and New-Onset Chronic Kidney Disease among Non-Diabetic Japanese Adults. *Sci Rep* **2023**, *13*, 13770, doi:10.1038/s41598-023-40300-8.

12. Okawa, Y.; Mitsuhashi, T. Association between Blood Pressure and New Onset of Chronic Kidney Disease in Non-Diabetic Japanese Adults: A Population-Based Longitudinal Study from 1998 to 2023. *Nutrition, Metabolism and Cardiovascular Diseases* **2024**, S093947532400173X, doi:10.1016/j.numecd.2024.05.005.

13. American Diabetes Association Professional Practice Committee; ElSayed, N.A.; Aleppo, G.; Bannuru, R.R.; Bruemmer, D.; Collins, B.S.; Ekhlaspour, L.; Gaglia, J.L.; Hilliard, M.E.; Johnson, E.L.; et al. 2. Diagnosis and Classification of Diabetes: *Standards of Care in Diabetes—2024*. *Diabetes Care* **2024**, *47*, S20–S42, doi:10.2337/dc24-S002.

14. Aygun, S.; Tokgozoglu, L. Comparison of Current International Guidelines for the Management of Dyslipidemia. *JCM* **2022**, *11*, 7249, doi:10.3390/jcm11237249.

15. Okamura, T.; Tsukamoto, K.; Arai, H.; Fujioka, Y.; Ishigaki, Y.; Koba, S.; Ohmura, H.; Shoji, T.; Yokote, K.; Yoshida, H.; et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. *JAT* **2024**, *31*, 641–853, doi:10.5551/jat.GL2022.

16. Stevens, P.E.; Ahmed, S.B.; Carrero, J.J.; Foster, B.; Francis, A.; Hall, R.K.; Herrington, W.G.; Hill, G.; Inker, L.A.; Kazancıoğlu, R.; et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International* **2024**, *105*, S117–S314, doi:10.1016/j.kint.2023.10.018.

17. World Health Organization Obesity and Overweight Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 23 October 2024).

18. Arnett, D.K.; Blumenthal, R.S.; Albert, M.A.; Buroker, A.B.; Goldberger, Z.D.; Hahn, E.J.; Himmelfarb, C.D.; Khera, A.; Lloyd-Jones, D.; McEvoy, J.W.; et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* **2019**, *140*, doi:10.1161/CIR.0000000000000678.

19. Kashiwagi, A.; Kasuga, M.; Araki, E.; Oka, Y.; Hanafusa, T.; Ito, H.; Tominaga, M.; Oikawa, S.; Noda, M.; Kawamura, T.; et al. International Clinical Harmonization of Glycated Hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program Values. *Journal of Diabetes Investigation* **2012**, *3*, 39–40, doi:10.1111/j.2040-1124.2012.00207.x.

20. Schoenfeld, D. Partial Residuals for the Proportional Hazards Regression Model. *Biometrika* **1982**, *69*, 239–241, doi:10.1093/biomet/69.1.239.

21. Akaike, H. A New Look at the Statistical Model Identification. *IEEE Trans. Automat. Contr.* **1974**, *19*, 716–723, doi:10.1109/TAC.1974.1100705.

22. Schwarz, G. Estimating the Dimension of a Model. *Ann. Statist.* **1978**, *6*, doi:10.1214/aos/1176344136.

23. Liyanage, T.; Toyama, T.; Hockham, C.; Ninomiya, T.; Perkovic, V.; Woodward, M.; Fukagawa, M.; Matsushita, K.; Praditpornsilpa, K.; Hooi, L.S.; et al. Prevalence of Chronic Kidney Disease in Asia: A Systematic Review and Analysis. *BMJ Glob Health* **2022**, *7*, e007525, doi:10.1136/bmjgh-2021-007525.

24. von Hippel, P.T. How Many Imputations Do You Need? A Two-Stage Calculation Using a Quadratic Rule. *Sociological Methods & Research* **2020**, *49*, 699–718, doi:10.1177/0049124117747303.

25. Python Software Foundation Python Available online: https://www.python.org/ (accessed on 23 October 2024).

26. Schemdraw Documentation — Schemdraw 0.19 Documentation Available online: https://schemdraw.readthedocs.io/en/latest/index.html (accessed on 30 September 2024).

27. Vandenbroucke, J.P.; von Elm, E.; Altman, D.G.; Gøtzsche, P.C.; Mulrow, C.D.; Pocock, S.J.; Poole, C.; Schlesselman, J.J.; Egger, M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. *Epidemiology* **2007**, *18*, 805–835, doi:10.1097/EDE.0b013e3181577511.

28. Cheng, Y.J.; Kanaya, A.M.; Araneta, M.R.G.; Saydah, S.H.; Kahn, H.S.; Gregg, E.W.; Fujimoto, W.Y.; Imperatore, G. Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016. *JAMA* **2019**, *322*, 2389, doi:10.1001/jama.2019.19365.

29. Hernán, M.A. The Hazards of Hazard Ratios. *Epidemiology* **2010**, *21*, 13–15, doi:10.1097/EDE.0b013e3181c1ea43.

30. Seki, M.; Nakayama, M.; Sakoh, T.; Yoshitomi, R.; Fukui, A.; Katafuchi, E.; Tsuda, S.; Nakano, T.; Tsuruya, K.; Kitazono, T. Blood Urea Nitrogen Is Independently Associated with Renal Outcomes in Japanese Patients with Stage 3–5 Chronic Kidney Disease: A Prospective Observational Study. *BMC Nephrol* **2019**, *20*, 115, doi:10.1186/s12882-019-1306-1.

31. Johnson, R.J.; Sanchez Lozada, L.G.; Lanaspa, M.A.; Piani, F.; Borghi, C. Uric Acid and Chronic Kidney Disease: Still More to Do. *Kidney International Reports* **2023**, *8*, 229–239, doi:10.1016/j.ekir.2022.11.016.

32. Mosenzon, O.; Cheng, A.Y.; Rabinstein, A.A.; Sacco, S. Diabetes and Stroke: What Are the Connections? *J Stroke* **2023**, *25*, 26–38, doi:10.5853/jos.2022.02306.

33. Tomic, D.; Shaw, J.E.; Magliano, D.J. The Burden and Risks of Emerging Complications of Diabetes Mellitus. *Nat Rev Endocrinol* **2022**, *18*, 525–539, doi:10.1038/s41574-022-00690-7.

**Figure 1**. Flow diagram of the study participants.

**Figure 2.** Kaplan–Meier curves stratified by dyslipidemia categories.

Table 1. Descriptive statistics of all observations stratified by dyslipidemia classification of 5970 non-diabetic Japanese citizens of Zentsuji City (1998–2024)

| | Dyslipidemia classification* | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | No dyslipidemia | | | Dyslipidemia | | | Total | | |
| | Failure | PY | IR† | Failure | PY | IR† | Failure | PY | IR† |
| Time at risk | | | | | | | | | |
|   Total | | 23077.1 | | | 19278.2 | | | 42355.3 | |
|   Minimum | | 0.47 | | | 0.40 | | | 0.40 | |
|   Maximum | | 25.4 | | | 24.7 | | | 25.5 | |
|   Mean | | 5.39 | | | 4.85 | | | 7.09 | |
|   Median | | 4.06 | | | 3.83 | | | 6.04 | |
| Failure/IR† | 940 | | 40.7 | 950 | | 49.3 | 1890 | | 44.6 |
| Sex | | | | | | | | | |
|   Female | 369 | 9253.9 | 39.9 | 400 | 7963.2 | 50.2 | 769 | 17217.0 | 44.7 |
|   Male | 571 | 13823.2 | 41.3 | 550 | 11315.0 | 48.6 | 1121 | 25138.3 | 44.6 |
| Age, mean (SD) | 66.0 | (11.4) | | 66.5 | (10.1) | | 66.2 | (10.8) | |
| BMI category‡ | | | | | | | | | |
|   Normal weight | 726 | 18969.6 | 38.3 | 642 | 14016.8 | 45.8 | 1368 | 32986.4 | 41.5 |
|   Overweight or obesity | 214 | 4107.5 | 52.1 | 308 | 5261.4 | 58.5 | 522 | 9368.9 | 55.7 |
| Self-reported alcohol intake | | | | | | | | | |
|   Non- or seldom-drinker | 552.6 | 12316.4 | 44.9 | 591.2 | 11361.9 | 52.0 | 1143.8 | 23678.3 | 48.3 |
|   Drinker | 387.4 | 10760.7 | 36.0 | 358.8 | 7916.3 | 45.3 | 746.2 | 18677.0 | 40.0 |
| Self-reported smoking status | | | | | | | | | |
|   Non- or ex-smoker | 853.8 | 19875.1 | 43.0 | 858.9 | 16623.7 | 51.7 | 1712.7 | 36498.8 | 46.9 |
|   Smoker | 86.2 | 3202.0 | 26.9 | 91.1 | 2654.5 | 34.3 | 177.3 | 5856.5 | 30.3 |
| Blood pressure category¶ | | | | | | | | | |
|   Normal | 408 | 12577.1 | 32.4 | 387 | 8731.7 | 44.3 | 795 | 21308.8 | 37.3 |
|   Hypertensive | 532 | 10500.1 | 50.7 | 563 | 10546.4 | 53.4 | 1095 | 21046.5 | 52.0 |
| HbA1c, mean (SD) | 5.53 | (0.34) | | 5.58 | (0.33) | | 5.55 | (0.34) | |
| AST, mean (SD) | 23.3 | (17.2) | | 23.9 | (9.92) | | 23.6 | (14.4) | |
| ALT, mean (SD) | 18.9 | (15.9) | | 21.8 | (15.0) | | 20.2 | (15.6) | |
| gGTP, mean (SD) | 29.1 | (34.4) | | 34.4 | (46.3) | | 31.5 | (40.2) | |
| Residential district | | | | | | | | | |
|   East | 165.6 | 4332.8 | 38.2 | 187.9 | 3556.5 | 52.8 | 353.5 | 7889.3 | 44.8 |
|   Tatsukawa | 162.5 | 3700.8 | 43.9 | 151.6 | 2996.1 | 50.6 | 314.1 | 6696.9 | 46.9 |
|   South | 137.4 | 3898.9 | 35.2 | 156.7 | 3376.7 | 46.4 | 294.1 | 7275.6 | 40.4 |
|   Fudeoka | 101.0 | 2916.7 | 34.6 | 96.4 | 2274.3 | 42.4 | 197.4 | 5191.1 | 38.0 |
|   Central | 103.5 | 2292.9 | 45.2 | 117.6 | 2096.2 | 56.1 | 221.1 | 4389.1 | 50.4 |
|   West | 97.7 | 2351.0 | 41.6 | 89.8 | 1775.0 | 50.6 | 187.6 | 4126.0 | 45.5 |
|   Yoshiwara | 88.9 | 2075.5 | 42.8 | 85.0 | 1828.6 | 46.5 | 173.9 | 3904.1 | 44.5 |
|   Yogita | 83.5 | 1508.6 | 55.3 | 64.8 | 1374.6 | 47.1 | 148.3 | 2883.2 | 51.4 |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; gGTP, gamma-glutamyl transferase; HbA1c, hemoglobin A1C; HDL, high-density lipoprotein cholesterol; IR, incidence rate; LDL, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; TG, triglycerides.

Results for multiple imputed variables (self-reported alcohol intake, self-reported smoking status, and residential district) are averaged over 30 imputations.

*Dyslipidemia is defined as LDL ≥140 mg/dL, HDL < 40 mg/dL, and/or TG ≥150 mg/dL.

†Incidence rate is reported per 1000 person-years.

‡Overweight or obesity is defined as a BMI ≥25 kg/m$^2$.

¶Hypertension is defined as SBP ≥130 mmHg and/or DBP ≥80mmHg.

**Table 2**. Association between dyslipidemia and subsequent development of chronic kidney disease (eGFR < 60 mL/min/1.73 $m^2$), using the Weibull accelerated failure-time model (Zentsuji, Kagawa Prefecture, Japan, 1998–2024)

| Variable | Total (n=5970) | | | Crude | Model 1 | Model 2 | Model 3 | Model 4 |
|---|---|---|---|---|---|---|---|---|
| | Person-years | Failures | IR¶ | TR (95% CI) | aTR (95% CI) | aTR (95% CI) | aTR (95% CI) | aTR (95% CI) |
| No dyslipidemia (reference) | 23077.1 | 940 | 40.7 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Dyslipidemia† | 19278.2 | 950 | 49.3 | 0.97 (0.95–0.98) | 0.96 (0.95–0.98) | 0.97 (0.95–0.98) | 0.96 (0.95–0.98) | 0.95 (0.93–0.97) |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; aTR, adjusted time ratio; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; gGTP, gamma-glutamyl transferase; HbA1c, hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; IR, incidecnce rate; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglycerides; TR, time ratio.

*Dyslipidemia was defined as LDL-C ≥140 mg/dL, HDL-C < 40 mg/dL, and/or TG ≥150 mg/dL.

†Overweight or obesity was defined as BMI ≥25 kg/$m^2$.

‡Hypertension was defined as SBP ≥130 mmHg and/or DBP ≥80 mmHg.

¶Incidence rate is reported per 1000 person-years.

Model 1 was adjusted for sex (male [reference]/female) and age. A multiplicative term (dyslipidemia* × sex) was added.

Model 2 was adjusted for both variables of Model 1, overweight or obesity (no [reference]/yes)†, self-reported smoking status (non- or ex-smoker [reference]/smoker), and self-reported alcohol intake (non- or seldom-drinker [reference]/drinker). A multiplicative term (dyslipidemia* × sex) was added.

Model 3 was adjusted for all variables of Model 2, hypertension (no [reference]/yes)‡, HbA1c, AST, ALT, and gGTP. A multiplicative term (dyslipidemia* × sex) was added.

Model 4 was adjusted for all variables of Model 3 and the residential area of the city. The multiplicative terms (dyslipidemia* × sex, dyslipidemia* × hypertension‡) were added.